The vision of something unique
medical model of the century.
Customization is the breakthrough that is driving the medical industry of the future.
A better understanding of each individual and their pathologies because of increasingly precise diagnoses permits surgeons to steer a patient toward a more specific and individualized treatment. The singularity of each patient is analyzed in greater depth, so that the patient can then receive the personalized treatment with the highest chance of success. The medical world has been waiting for the arrival of customization in spinal surgery. With scientific progress in understanding sagittal balance and spinal injury, combined with the advent of new digital technologies, it is now possible to offer spinal patients entirely customized implants.
But to understand this complex field, to bring together and integrate all the puzzle pieces, it is necessary to commit to a complete process, blending R&D with the industrial dimension. To achieve this combination, a company has to bet on the future with a far-reaching vision. I am proud to say that we at Medicrea have done exactly that!
Customized spinal rods in 2013, morphologically adapted 3D implants in 2014 – with these innovations we proved our team is the industry leader in spinal surgery products and services. The UNiD concept of a fully customizable surgical rod represents a new era in our relationship with our clients: by forming a planning partnership with our surgeons, we can now offer them a combination of innovative products and complete services – for before, during and after spinal surgery.
We are a young business, but we are also bold, and we aim to see far into the future of the industry. We dream, but most of all, we act. We have our head in the stars, but our feet firmly planted on the ground.
Let’s continue to improve this field together and to honor our promise every day. (IM)PROVE!
If we can dream it, we can do it.
Denys SOURNAC, CEO
The parent company of the MEDICREA Group, based in Rillieux-la-Pape (France), MEDICREA International performs the export distribution, marketing, research & development, monitoring of clinical studies, the logistics platform and the administrative and financial functions for various entities.
MEDICREA USA Created in 2006, 39 employees
Joe WALLAND, CEO
Based in New York (United States), MEDICREA USA has been operating since 2007. It promotes implants designed and developed by the Group and distributes them in the United States. The company also takes part in clinical trials carried out in the US. Departments : Finance, Marketing, Sales, Logistics and Clinical Research.
We specialize in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. We stand apart by providing personalized treatment modalities that are effectively adapted to the unique anatomical requirements of each patient. Through the lens of predictive medicine, we lead the design, manufacture, and distribution of patient specific implant technologies. By leveraging our proprietary software analysis tools with big data and deep learning technologies we are well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.
In our efforts, we, at Medicrea, strive to provide products of excellence that meet our high quality and regulatory standards as well as those of our customers. In a process of continuous improvement, we listen to our customers and treat every request with the utmost level of professionalism.
Mentor employees and partners in adaptive spine intelligence
Pioneer corporate know-how and healthcare efficiencies
Recruit dynamic minds to develop and commercialize innovation
Operate in compliance with all industry standards and guidelines
Validate a new standard of surgeon and industry collaboration
Engage all involved to strengthen our systems-based approach
Launch of proprietary UNiD HUB software for surgical planning based on big data technologies
FDA approvals for 3D-printed titanium interbody devices and PASS TULIP top-loading fixation system
German subsidiary is founded in Cologne
U.S. Launch of New Generation LigaPASS band
LigaPASS system FDA cleared in idiopathic adolescent indications
Patient Specific 3D printed interbody fusion device world premiere
K-JAWS® obtains 510k for US market
30M$ turnover milestone / 55% of revenue in the US
First UNiD patient specific rod surgery in Lyon France (Sept-18th)
PASS OCT CE marked and FDA cleared and first surgeries
PASS LP FDA cleared in idiopathic adolescent indications
LigaPASS system FDA cleared
PASS MIS minimally invasive system FDA cleared
LigaPASS system CE marked
CE marking of the IMPIX Manta+ – first prefilled cervical cage on single use holder
New MEDICREA international headquarters in Lyon (France)
15M$ turnover milestone / 45% of revenue in the US
CE marking of the Granvia-C cervical dics prosthesis
CE marking of the IMPIX-TLIF lumbar cage
FDA approval of the PASS LP thoracolumbar fixation system and its Clement derotation connector
C-JAWS® FDA cleared
Medicrea IPO on NYSE ALTERNEXT
US subsidiary is founded in New-York
French subsidiary is founded in Lyon
CE marking of PASS LP thoracolumbar fixation system – new major release in the PASS technology platform
CE marking of the IMPIX-C+ – first prefilled cervical cage on the spinal market
UK subsidiary is Founded in Cambridge
CE marking of the C-Jaws, compressive cervical staple